PRESS RELEASE - November 6, 2024 - 1:15pm CET - Montpellier, France - Euronext Paris: MEDCL




Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone
Reached for Olanzapine LAI clinical Phase 3


Medincell’s partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information:

About UZEDY®
• Updated 2024 Revenue Outlook: Increased from $80 million to $100 million
o U.S. Revenues Year-to-Date 2024: $75 million
o U.S. Revenues for Q3 2024: $35 million
• Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial
milestones

About Olanzapine Long-Acting Injectable (TV-‘749 / mdc-TJK)
• Completion of 100% of targeted injections for submission without PDSS*



Teva Q3 results press release: https://ir.tevapharm.com/news-and-events/press-releases/press-release-
details/2024/Teva-Announces-Strong-Financial-Results-for-the-Third-Quarter-of-2024-led-by-Generics-
Performance-and-Innovative-Portfolio-Growth-Raises-2024-Financial-Outlook-including-on-Revenues-Adjusted-
EBITDA-and-Non-GAAP-EPS/default.aspx


Teva Q3 2024 earnings conference call today at 8:00am ET, webcast and replay:
https://events.q4inc.com/attendee/714898512


*
Post-Injection Delirium/Sedation Syndrome (PDSS) is a rare but significant complication associated with existing long-acting
injectable formulation of olanzapine. PDSS occurs when a portion of the injected medication unintentionally enters the
bloodstream too quickly, causing sudden sedation, confusion, and potentially serious side effects such as respiratory issues. For
healthcare providers and patients, PDSS remains a barrier to the widespread use of olanzapine LAI. The requirement for close
post-injection monitoring limits the convenience and flexibility of this treatment option. Medincell’s olanzapine LAI is designed to
eliminate the risk of PDSS, potentially making it a safer and more accessible treatment option.




About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in
many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the
effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical
ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days,
weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first
treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and
is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name
SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new
treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different
nationalities.

UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals

medincell.com


Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG




1/2
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94




This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical
benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv)
its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters
regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be
contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's
financial capabilities.
These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", “expect”, "foresee",
"aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", “potential”, "should", "could" and other words and phrases of the same meaning or used in negative
form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ
materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found
in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered
with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In
particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.
Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation
to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in
the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to
such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.
This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's
shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment
objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this
document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions.




2/2